Neurotechnology company CranioSense has been awarded approximately $5.5 million in non-dilutive funding through the NIH Blueprint MedTech Program and the U.S. Department of Defense's Joint Warfighter ...
House Speaker Mike Johnson (R-LA) emphasized Friday that the Republican failure to secure President Donald Trump’s redistricting plan in Indiana was not indicative of a loss of power leading up to the ...
Johnson & Johnson’s billion-dollar bet on a novel implant for heart failure hit a roadblock this week, with an FDA advisory panel unanimously voting against its risk-benefit profile. The V-Wave ...
An FDA advisory panel gave a unanimous verdict for an interatrial shunt in heart failure: no way. All 15 members of the Circulatory System Devices Panel of the Medical Devices Advisory Committee on ...
Please provide your email address to receive an email when new articles are posted on . An FDA advisory panel voted 0-15 against approving an interatrial shunt to improve symptoms and prognosis in ...
FDA advisors on Wednesday will deliberate on whether shunt therapy still has a narrow path forward in heart failure after a disappointing pivotal trial. In its premarket approval application for the ...
Approximately 36,500 shunts are implanted each year in the U.S. and the U.K in patients with elevated intracranial pressure. 30-40% of shunts fail within the first year, resulting in elevated ...
Weight loss is the only proven disease-modifying strategy for Idiopathic Intracranial Hypertension (IIH). A 5%–10% reduction in total body weight can lead to significant improvement in papilledema, ...
TUESDAY, Sept. 23, 2025 (HealthDay News) -- Shunt surgery significantly improves gait velocity at three months among patients with idiopathic normal-pressure hydrocephalus with a response to temporary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback